- Home
- VRNS vs HALO Comparison
VRNS vs HALO Comparison
Compare VRNS & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNS
- HALO
- Stock Information
- Founded
- VRNS 2004
- HALO 1998
- Country
- VRNS United States
- HALO United States
- Employees
- VRNS N/A
- HALO N/A
- Industry
- VRNS Computer Software: Prepackaged Software
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRNS Technology
- HALO Health Care
- Exchange
- VRNS Nasdaq
- HALO Nasdaq
- Market Cap
- VRNS 5.6B
- HALO 6.4B
- IPO Year
- VRNS 2014
- HALO N/A
- Fundamental
- Price
- VRNS $46.91
- HALO $48.78
- Analyst Decision
- VRNS Buy
- HALO Buy
- Analyst Count
- VRNS 17
- HALO 9
- Target Price
- VRNS $58.88
- HALO $61.11
- AVG Volume (30 Days)
- VRNS 1.5M
- HALO 1.5M
- Earning Date
- VRNS 02-03-2025
- HALO 10-31-2024
- Dividend Yield
- VRNS N/A
- HALO N/A
- EPS Growth
- VRNS N/A
- HALO 61.71
- EPS
- VRNS N/A
- HALO 3.02
- Revenue
- VRNS $546,535,000.00
- HALO $947,355,000.00
- Revenue This Year
- VRNS $14.01
- HALO $23.36
- Revenue Next Year
- VRNS $11.79
- HALO $15.15
- P/E Ratio
- VRNS N/A
- HALO $16.09
- Revenue Growth
- VRNS 12.07
- HALO 21.35
- 52 Week Low
- VRNS $41.13
- HALO $33.15
- 52 Week High
- VRNS $60.58
- HALO $65.53
- Technical
- Relative Strength Index (RSI)
- VRNS 30.44
- HALO 46.87
- Support Level
- VRNS $46.83
- HALO $47.55
- Resistance Level
- VRNS $50.69
- HALO $48.88
- Average True Range (ATR)
- VRNS 1.13
- HALO 1.20
- MACD
- VRNS -0.10
- HALO 0.30
- Stochastic Oscillator
- VRNS 2.75
- HALO 63.47
About VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.